Laura Huff, MD
Dermatology · Boulder, CONPI 1538458963
Payments from drug & device makers
Across 153 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$730
- AbbVie$514
- Galderma Laboratories, L.p.$492
- Regeneron Healthcare Solutions, Inc.$354
- Sanofi$227
- Sun Pharmaceutical Industries Inc.$165
- plus $904 from 18 others
What the payments were for
- Food & beverage$3,09091%
- Education$2959%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $730 |
| AbbVie | 23 | $514 |
| Galderma Laboratories, L.p. | 20 | $492 |
| Regeneron Healthcare Solutions, Inc. | 11 | $354 |
| Sanofi | 11 | $227 |
| Sun Pharmaceutical Industries Inc. | 8 | $165 |
| Johnson & Johnson | 4 | $118 |
| Amgen | 6 | $114 |
| Novartis | 5 | $103 |
| Incyte Corporation | 6 | $89 |
| Sanofi-aventis U.S. LLC | 1 | $72 |
| E.r. Squibb & Sons, L.L.C. | 3 | $69 |
| Pfizer | 4 | $62 |
| LEO Pharma Inc. | 2 | $52 |
| Journey Medical Corporation | 2 | $37 |
| DUSA Pharmaceuticals, Inc. | 2 | $37 |
| Biofrontera Inc. | 1 | $25 |
| VYNE Pharmaceuticals Inc. | 1 | $23 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $20 |
| Almirall LLC | 1 | $18 |
| UCB, Inc. | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $13 |
How this compares
$3,386 in reported general payments places this provider in the 55th percentile of 280 dermatology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 11 | $221,061 |
| Cosentyx Unoready PenSecukinumab | 11 | $106,393 |
| Clobetasol Propionate | 67 | $2,052 |
| Fluorouracil | 16 | $1,118 |
| Triamcinolone Acetonide | 82 | $1,037 |
| Ketoconazole | 28 | $948 |
| Metronidazole | 16 | $863 |
| ValacyclovirValacyclovir Hcl | 26 | $802 |
| Clindamycin Phosphate | 11 | $397 |
| Hydrocortisone | 34 | $219 |
| Mupirocin | 21 | $183 |
| Finasteride | 24 | $172 |
| Fluconazole | 16 | $87 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Boulder
- Cathy KogerBoulder$182K
- Marcjonathan SerotaLittleton$3.2M
- Stanca BirleaAurora$1.9M
- James SwinehartDenver$931K
- Theodore AlkousakisAurora$880K
- Ammon LarsenLoveland$620K
- Victoria MossColorado Springs$473K
- James JensenCastle Rock$380K
- Cory DunnickAurora$366K
- Kimberly NeymanWheat Ridge$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.